Sun Pharma gains on patent litigation settlement with Actavis

Shares of drug maker Sun Pharma are trading higher by nearly 2% to Rs 913 on the BSE after Ranbaxy Pharmaceuticals, its US subsidiary,and its partners Cipher Pharmaceuticals Inc. (Cipher) and Galephar Pharmaceutical Research, Inc. (Galephar) settled a patent litigation with Actavis over the generic version of Absorica, a drug used to treat acne Absorica (isotretinoin capsules).

Under the agreement, Ranbaxy and its partners along with Actavis entered into a non-exclusive pact which will permit Actavis to sell the generic version of Absorica in December 2020 which is nine months before the expiry of patent.

Earlier, Sun Pharma had made a tender offer to acquire US-based eyecare firm InSite Vision for USD 0.35 per share in cash.

The stock opened at Rs 909.90 and touched a high of Rs 915.90 on the BSE. A total of 114,802 shares changed hands on the BSE so far.

Business Standard is now on Telegram.
For insightful reports and views on business, markets, politics and other issues, subscribe to our official Telegram channel